T. Rowe Price Associates
HHS icon

T. Rowe Price Associates’s Harte-Hanks HHS Stock Holding History

T. Rowe Price Associates’s Portfolio HHS Stock Details HHS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-2,975
Closed -$32K – 2586
2017
Q3 		$32K Hold
2,975
– – ﹤0.01% 2560
2017
Q2 		$31K Hold
2,975
– – ﹤0.01% 2546
2017
Q1 		$42K Hold
2,975
– – ﹤0.01% 2548
2016
Q4 		$45K Hold
2,975
– – ﹤0.01% 2528
2016
Q3 		$48K Sell
2,975
-10
-0.3% -$165 ﹤0.01% 2499
2016
Q2 		$47K Hold
2,985
– – ﹤0.01% 2480
2016
Q1 		$76K Hold
2,985
– – ﹤0.01% 2442
2015
Q4 		$97K Buy
2,985
+10
+0.3% +$374 ﹤0.01% 2428
2015
Q3 		$105K Hold
2,975
– – ﹤0.01% 2400
2015
Q2 		$177K Buy
2,975
+300
+11% +$20.2K ﹤0.01% 2374
2015
Q1 		$209K Hold
2,675
– – ﹤0.01% 2336
2014
Q4 		$207K Hold
2,675
– – ﹤0.01% 2341
2014
Q3 		$170K Hold
2,675
– – ﹤0.01% 2382
2014
Q2 		$192K Hold
2,675
– – ﹤0.01% 2361
2014
Q1 		$236K Hold
2,675
– – ﹤0.01% 2257
2013
Q4 		$209K Hold
2,675
– – ﹤0.01% 2299
2013
Q3 		$236K Hold
2,675
– – ﹤0.01% 2203
2013
Q2 		$230K Buy
+2,675
New +$221K ﹤0.01% 2163

Other funds holding HHS

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FM
Fondren Management Houston, Texas $16.9M AUM 5.82% 1-Year Est. Return
VCA
VIEX Capital Advisors Sunny Isles Beach, Florida $30.9M AUM 55.48% 1-Year Est. Return
EVC
Eidelman Virant Capital Saint Louis, Missouri $136M AUM 15.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Foundry Partners Minneapolis, Minnesota $1.89B AUM 9.84% 1-Year Est. Return

T. Rowe Price Associates's HHS Position: Q4 2017 in Review

T. Rowe Price Associates sold out of Harte-Hanks (HHS) in Q4 2017, closing a stake of 2,975 shares — an estimated $32K sold.

T. Rowe Price Associates first reported a position in HHS in Q2 2013 and held it in 18 quarters. The position peaked at $236K in Q1 2014. 48 funds tracked by Wall St. Rank hold HHS as of Q4 2017.

  • T. Rowe Price Associates reported no remaining Harte-Hanks position as of Q4 2017 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,975 Harte-Hanks shares in Q4 2017, an estimated $32K.
  • T. Rowe Price Associates first reported a position in Harte-Hanks in Q2 2013 and held it in 18 quarters.
  • T. Rowe Price Associates's Harte-Hanks position peaked at $236K in Q1 2014.
  • 48 funds tracked by Wall St. Rank held Harte-Hanks as of Q4 2017.

Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.